Engineering N-terminal Domain of Tissue Inhibitor of Metalloproteinase (TIMP)-3 to Be a Better Inhibitor Against Tumour Necrosis Factor-alpha-converting Enzyme
Overview
Authors
Affiliations
We previously reported that full-length tissue inhibitor of metalloproteinase-3 (TIMP-3) and its N-terminal domain form (N-TIMP-3) displayed equal binding affinity for tissue necrosis factor-alpha (TNF-alpha)-converting enzyme (TACE). Based on the computer graphic of TACE docked with a TIMP-3 model, we created a number of N-TIMP-3 mutants that showed significant improvement in TACE inhibition. Our strategy was to select those N-TIMP-3 residues that were believed to be in actual contact with the active-site pockets of TACE and mutate them to amino acids of a better-fitting nature. The activities of these mutants were examined by measuring their binding affinities (K(app)(i)) and association rates (k(on)) against TACE. Nearly all mutants at position Thr-2 exhibited slightly impaired affinity as well as association rate constants. On the other hand, some Ser-4 mutants displayed a remarkable increase in their binding tightness with TACE. In fact, the binding affinities of several mutants were less than 60 pM, beyond the sensitivity limits of fluorimetric assays. Further studies on cell-based processing of pro-TNF-alpha demonstrated that wild-type N-TIMP-3 and one of its tight-binding mutants, Ser-4Met, were capable of inhibiting the proteolytic shedding of TNF-alpha. Furthermore, the Ser-4Met mutant was also significantly more active (P<0.05) than the wild-type N-TIMP-3 in its cellular inhibition. Comparison of N-TIMP-3 and full-length TIMP-3 revealed that, despite their identical TACE-interaction kinetics, the latter was nearly 10 times more efficient in the inhibition of TNF-alpha shedding, with concomitant implications for the importance of the TIMP-3 C-terminal domain in vivo.
Engineering Selective TIMPs Using a Counter-Selective Screening Strategy.
Ahmadighadykolaei H, Radisky E, Raeeszadeh-Sarmazdeh M Methods Mol Biol. 2023; 2747:257-278.
PMID: 38038946 PMC: 11235094. DOI: 10.1007/978-1-0716-3589-6_20.
The Role of CX3CL1 and ADAM17 in Pathogenesis of Diffuse Parenchymal Lung Diseases.
Urban J, Suchankova M, Ganovska M, Leksa V, Sandor F, Tedlova E Diagnostics (Basel). 2021; 11(6).
PMID: 34208027 PMC: 8230701. DOI: 10.3390/diagnostics11061074.
Casagrande V, Iuliani G, Menini S, Pugliese G, Federici M, Menghini R Clin Transl Med. 2021; 11(2):e305.
PMID: 33634991 PMC: 7862169. DOI: 10.1002/ctm2.305.
Strategies to Target ADAM17 in Disease: From its Discovery to the iRhom Revolution.
Calligaris M, Cuffaro D, Bonelli S, Spano D, Rossello A, Nuti E Molecules. 2021; 26(4).
PMID: 33579029 PMC: 7916773. DOI: 10.3390/molecules26040944.
Rai G, Baird S Clin Exp Metastasis. 2020; 37(1):69-76.
PMID: 31894441 DOI: 10.1007/s10585-019-10017-y.